Gubra receives $50M milestone payment from AbbVie for Phase 2 weight-loss drug trial

Danish biotech firm Gubra has triggered a $50 million milestone payment following partner AbbVie's initiation of a Phase 2 clinical trial for a weight-loss therapeutic. The payment confirms the advancement of the drug candidate into mid-stage human testing, though efficacy and regulatory approval remain uncertain.